瑞典北部新生儿接种卡介苗(1927-1931):历史数据再分析揭示接种者死亡率较低
该研究再分析1927-1931年瑞典北博滕地区新生儿口服卡介苗(BCG)推广的历史数据,按接种状态分析死后新生儿死亡率。结果显示BCG接种覆盖率为28.3%,BCG/未接种的死后新生儿死亡风险比(RR)为0.53(0.45-0.62),且与结核病死亡减少80%(49-92%)相关;1930-1931年数据提示BCG对非结核感染性死亡(RR=0.75,0.58-0.97)和呼吸道感染死亡(RR=0.61,0.43-0.84)有保护作用。
要点
- 1930-1931年数据提示BCG对非结核感染性死亡和呼吸道感染死亡有保护作用。
- 1927-1929年非感染性死亡保护极强(RR=0.09),提示健康接种者偏倚。
核心结论
- 健康接种者偏倚尤其使1927-1929年BCG总体效果被高估,但1930-1931年数据部分支持BCG可预防结核病死亡和呼吸道感染死亡。
研究设计与样本
- 基于Carl Näslund博士三篇论文的历史数据再分析,纳入瑞典北博滕地区1927-1931年新生儿,按口服BCG接种状态分析死后新生儿死因别死亡率,并排除先天性疾病死亡。
主要发现
- BCG覆盖率为28.3%(5659/20012),总死亡率为8.7%(1746/20012)。
临床怎么用
- 解读历史BCG非特异性效应研究时需警惕健康接种者偏倚,尤其早期数据可能高估保护效果。
- BCG对呼吸道感染死亡的保护信号需在当代人群中进一步验证,不宜直接外推。
局限性
- 为历史数据再分析,原始研究非随机设计,存在健康接种者偏倚等混杂。
- 研究期间效果不一致,1927-1929年数据偏倚明显,1930-1931年样本量有限。
- 脑膜炎死亡增加等非预期结果需谨慎解释。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Following the introduction of oral Bacille Calmette-Guérin (BCG) a century ago, Albert Calmette suggested that BCG both provided protection against death from tuberculosis (TB) and other causes. The findings were not pursued. Today, there is considerable evidence that intradermal BCG have beneficial non-specific effects (NSEs). We re-analyzed data from BCG's introduction 1927-1931 in Sweden hypothesizing that BCG reduced infectious deaths. METHODS: In three papers published by Dr Carl Näslund, the progress of oral neonatal BCG rollout provided free-of-charge and the effects on child mortality in the highly TB-prevalent region Norrbotten was sequentially updated. We analyzed cause-specific post-neonatal mortality by vaccination status excluding deaths from congenital conditions. Due to apparent differences in effects during study years, effects were assessed overall and separately in two periods (1927-1929, 1930-1931). RESULTS: According to Näslund, TB households were slightly more likely to accept vaccination; fewer newborns that were sick or had congenital problems were vaccinated. BCG coverage was 28.3% (5659/20,012); 8.7% (1746/20,012) died. The BCG/unvaccinated Risk Ratio (RR) of post-neonatal childhood death was 0.53 (0.45-0.62). BCG was associated with 80% (49-92%) reduced mortality from TB. From 1927 to 29, BCG appeared to protect strongly against deaths from all diseases, including the non-infectious, RR = 0.09 (0.02-0.36), presumably reflecting selection bias. From 1930 to 1931, there was no protection against non-infectious deaths, RR = 0.92 (0.49-1.70) indicating less bias (p = 0.004 for same effect). During 1930-1931, BCG was associated with reductions in non-TB infectious deaths (RR = 0.75 (0.58-0.97)); 2/3 were caused by respiratory infections, against which the BCG/unvaccinated RR was 0.61 (0.43-0.84). Other causes of death were less frequent and provided no clear pattern, except that BCG was associated with more meningitis deaths, RR = 6.85 (2.20-21.4). CONCLUSION: Healthy vaccinee bias, particularly in 1927-1929, resulted in strongly beneficial overall BCG effects. However, the 1930-1931 data provided some support that BCG both protected against TB deaths and deaths from respiratory infections.
引用
- Schaltz-Buchholzer F, Kjær Sørensen M, Benn CS, et al. The introduction of BCG vaccination to neonates in Northern Sweden, 1927-31: Re-analysis of historical data to understand the lower mortality among BCG-vaccinated children. Vaccine. 2021. PMID: 34134904. doi:10.1016/j.vaccine.2021.06.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。